In addition, the adamantane-based drugs, Vildagliptin [26] and Saxagliptin [27] are members of a new class of oral hypoglycemic agents known as dipeptidyl peptidase IV (DPP-IV) inhibitors, which were approved for the treatment of type 2 diabetes. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.